Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.

ABSTRACT:

Background

Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). However, the efficacy and safety of pralsetinib in real world has rarely been reported.

Materials and methods

This study reviewed the efficacy and safety of pralsetinib in RET fusion-positive NSCLC patients between March 2021 and December 2021. Progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and log-rank test. A Cox regression model was performed to identify independent prognostic factors.

Results

A total of 28 patients were enrolled, and the median follow-up time was 18.1 months. The objective response rate and dise

SUBMITTER: Wang L 

PROVIDER: S-EPMC11804255 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature